NewslettersImmunology of Infectious Disease NewsFDA Approves Direct Biologics to Proceed with a Landmark Phase III Acute Respiratory Distress Syndrome (ARDS) TrialBy Danielle Corrigan - April 22, 20220367Direct Biologics announced that the FDA has approved the company to proceed with its Phase III clinical trial using its investigational EV drug, ExoFlo, to treat ARDS due to COVID-19.[Direct Biologics]Press Release